TARS · Company research
Tarsus Pharmaceuticals, Inc. Common Stock (TARS): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 74.11 | $3,327,858,481.67 | 3123263481.67 | 96.2631578947368421 | — | — | 19.1353010814089885 | 9.5977829611054071 | 58.2261693262063890 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.